Business Description
AgomAb Therapeutics NV
ISIN : US00860C1027
Share Class Description:
AGMB: ADRTotal Employee Number:
62Description
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 92.88 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -68.3 | |||||
3-Year EPS without NRI Growth Rate | -85.4 | |||||
3-Year FCF Growth Rate | -30.9 | |||||
3-Year Book Growth Rate | 29.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 72.08 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.03 | |||||
9-Day RSI | 52.95 | |||||
14-Day RSI | 53.58 | |||||
3-1 Month Momentum % | -1.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.52 | |||||
Quick Ratio | 6.52 | |||||
Cash Ratio | 6.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 0.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -11.7 | |||||
ROA % | -10.35 | |||||
ROIC % | -47.05 | |||||
3-Year ROIIC % | 483.04 | |||||
ROC (Joel Greenblatt) % | -1042.77 | |||||
ROCE % | -11.24 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.16 | |||||
Price-to-Tangible-Book | 5.32 | |||||
EV-to-EBIT | -24.79 | |||||
EV-to-EBITDA | -24.68 | |||||
EV-to-Forward-EBITDA | -5.31 | |||||
EV-to-FCF | -8.4 | |||||
| Price-to-Net-Current-Asset-Value | 5.54 | |||||
| Price-to-Net-Cash | 5.81 | |||||
Earnings Yield (Greenblatt) % | -4.03 | |||||
FCF Yield % | -9.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGMB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AgomAb Therapeutics NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.418 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 53.58 | ||
| 14-Day ATR ($) | 1.430644 | ||
| 20-Day SMA ($) | 12.262 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 8.75 - 17.82 | ||
| Shares Outstanding (Mil) | 49.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AgomAb Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AgomAb Therapeutics NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 141 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 50 days | ||
| First quarter earnings results for 2026 | 2026-07-10 | 13.03 (-0.50%) | ||
| General meeting for 2026 | 2026-05-26 16:00 | 11.50 (+4.74%) | ||
| Guidance call for 2026 | 2026-05-20 08:00 | 10.51 (+0.86%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | 10.56 (+3.02%) | ||
| Annual report for 2025 | 2026-04-23 | 10.55 (-4.57%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-23 | 10.55 (-4.57%) |
Show
Entries
AgomAb Therapeutics NV Frequently Asked Questions
What is AgomAb Therapeutics NV(AGMB)'s stock price today?
The current price of AGMB is $13.08. The 52 week high of AGMB is $17.82 and 52 week low is $8.75.
When is next earnings date of AgomAb Therapeutics NV(AGMB)?
The next earnings date of AgomAb Therapeutics NV(AGMB) is 2026-08-31 Est..
Does AgomAb Therapeutics NV(AGMB) pay dividends? If so, how much?
AgomAb Therapeutics NV(AGMB) does not pay dividend.
Guru Commentaries on NAS:AGMB
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on AgomAb Therapeutics NV
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers